Your browser is no longer supported. Please, upgrade your browser.
IMMU Immunomedics, Inc. daily Stock Chart
IMMU [NASD]
Immunomedics, Inc.
Index- P/E- EPS (ttm)-1.44 Insider Own2.60% Shs Outstand122.98M Perf Week-6.14%
Market Cap1.35B Forward P/E- EPS next Y-0.26 Insider Trans-5.05% Shs Float116.14M Perf Month-3.93%
Income-153.20M PEG- EPS next Q-0.11 Inst Own75.40% Short Float25.64% Perf Quarter23.46%
Sales3.10M P/S436.38 EPS this Y-135.30% Inst Trans1.92% Short Ratio11.06 Perf Half Y116.32%
Book/sh-0.53 P/B- EPS next Y50.90% ROA-198.30% Target Price14.17 Perf Year380.35%
Cash/sh1.26 P/C8.73 EPS next 5Y- ROE182.10% 52W Range2.02 - 14.48 Perf YTD199.73%
Dividend- P/FCF- EPS past 5Y-44.67% ROI-200.90% 52W High-24.08% Beta1.55
Dividend %- Quick Ratio1.30 Sales past 5Y-37.60% Gross Margin84.40% 52W Low444.06% ATR0.74
Employees138 Current Ratio1.30 Sales Q/Q-33.30% Oper. Margin- RSI (14)42.53 Volatility7.52% 6.76%
OptionableYes Debt/Eq- EPS Q/Q-189.80% Profit Margin- Rel Volume0.56 Prev Close11.00
ShortableYes LT Debt/Eq- EarningsNov 15 AMC Payout- Avg Volume2.69M Price10.99
Recom1.30 SMA20-10.18% SMA50-2.99% SMA20041.59% Volume836,299 Change-0.09%
May-05-17Upgrade Wells Fargo Market Perform → Outperform
Oct-06-16Resumed Jefferies Buy
Jun-21-16Downgrade Wells Fargo Outperform → Market Perform
May-06-16Upgrade Jefferies Hold → Buy
Dec-04-15Downgrade Wells Fargo Outperform → Market Perform
Jul-29-15Downgrade Jefferies Buy → Hold
Aug-27-14Downgrade R. F. Lafferty Buy → Neutral $4
Jan-08-14Initiated Chardan Capital Markets Buy $9
Oct-02-13Reiterated Oppenheimer Outperform $6 → $8
Sep-10-13Initiated R. F. Lafferty Buy $8
Jun-03-13Initiated WallachBeth Buy $6
Aug-31-11Initiated Summer Street Research Buy $8
Jul-28-11Initiated Summer Street Research Buy $8
Jul-13-11Resumed Brean Murray Buy $8
May-17-11Initiated Oppenheimer Outperform $6
Feb-23-11Initiated Wedbush Outperform $6
Jul-03-07Initiated Brean Murray Buy $8
Feb-20-07Initiated Lazard Capital Buy $6
Oct-23-17 08:37AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? Zacks
Oct-05-17 12:21PM  Edited Transcript of IMMU earnings conference call or presentation 16-Aug-17 9:00pm GMT Thomson Reuters StreetEvents -8.50%
Oct-03-17 11:19AM  ETFs with exposure to Immunomedics, Inc. : October 3, 2017 Capital Cube
Sep-15-17 04:30PM  Why Carnival, Immunomedics, and Fitbit Slumped Today Motley Fool
08:00AM  Immunomedics Announces Agreements to Exchange Approximately $80.0 Million of Its 4.75% Convertible Senior Notes Due 2020 for Common Stock GlobeNewswire
Sep-11-17 09:00AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? Zacks +5.17%
07:00AM  Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer GlobeNewswire
Aug-30-17 08:00AM  Immunomedics to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-28-17 05:33PM  ETFs with exposure to Immunomedics, Inc. : August 28, 2017 Capital Cube +14.07%
03:30PM  Here's Why Immunomedics Rose as Much as 14.2% Today Motley Fool
Aug-24-17 12:51PM  Harry Boxer: These three biotech stocks are breaking out MarketWatch +9.88%
10:45AM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q4, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-23-17 08:48AM  Immunomedics (IMMU) Catches Eye: Stock Up 5.1% Zacks
08:41AM  Zacks.com featured highlights: Glu Mobile, Calumet Specialty Products Partners, The Bancorp, Immunomedics and Hudbay Minerals Zacks
Aug-22-17 10:44AM  Immunomedics' Progress in Phase II Cancer Study Encouraging Zacks +5.11%
08:23AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : August 22, 2017 Capital Cube
Aug-21-17 02:02PM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: 2017 By the Numbers : August 21, 2017 Capital Cube +7.01%
08:00AM  Immunomedics Announces Publication of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy as a Single Agent in Patients With Metastatic Colorectal Cancer GlobeNewswire
Aug-17-17 08:50AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? Zacks
Aug-16-17 09:21PM  Immunomedics, Inc. Value Analysis (NASDAQ:IMMU) : August 17, 2017 Capital Cube
09:14PM  Immunomedics reports 4Q loss Associated Press
04:00PM  Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline GlobeNewswire
Aug-07-17 04:00PM  Immunomedics Announces Conference Call and Webcast for Fourth Quarter and Fiscal Year 2017 Results GlobeNewswire
Aug-03-17 09:46AM  Immunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : August 3, 2017 Capital Cube
Jul-10-17 02:40PM  ETFs with exposure to Immunomedics, Inc. : July 10, 2017 Capital Cube
09:00AM  Published Results from Clinical Trials Demonstrate Therapeutic Potential for Immunomedics Sacituzumab Govitecan (IMMU-132) in the Treatment of Metastatic Solid Cancers GlobeNewswire
Jun-29-17 03:11PM  Immunomedics Announces Results of Special Stockholder Meeting GlobeNewswire
08:35AM  Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock Zacks
Jun-27-17 03:20PM  ETFs with exposure to Immunomedics, Inc. : June 27, 2017 Capital Cube
Jun-16-17 03:54PM  ETFs with exposure to Immunomedics, Inc. : June 16, 2017 Capital Cube
Jun-07-17 11:05AM  Three Junior Biotechs Ready to Run Investopedia
Jun-05-17 02:22PM  ETFs with exposure to Immunomedics, Inc. : June 5, 2017 Capital Cube
Jun-01-17 08:00AM  Immunomedics to Present at Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-26-17 09:33AM  Biotech Movers: Immunomedics, Aerie, Exelixis TheStreet.com
May-25-17 12:41PM  ETFs with exposure to Immunomedics, Inc. : May 25, 2017 Capital Cube
May-24-17 09:51AM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017 Capital Cube
May-18-17 05:00AM  Edited Transcript of IMMU earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-11-17 09:21PM  Edited Transcript of IMMU earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents +6.14%
May-10-17 04:10PM  Immunomedics reports 3Q loss Associated Press
04:00PM  Immunomedics Announces Third Quarter Fiscal 2017 Results and Clinical Program Developments GlobeNewswire
08:15AM  Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2017 Results GlobeNewswire
May-08-17 05:53PM  The Head-Scratching Reason Immunomedics Rose by as Much as 12% Motley Fool +8.02%
08:25AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : May 8, 2017 Capital Cube
08:00AM  Today's Research Report on Biotech Stocks to Watch: Immunomedics and Esperion Therapeutics Accesswire
06:00AM  Immunomedics Breaks Out, But Will It Last? Investopedia
May-06-17 09:10AM  Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated? 24/7 Wall St.
May-05-17 04:32PM  Immunomedics, Seattle Genetics Scrap License Deal TheStreet.com +17.56%
04:22PM  Why Immunomedics, MercadoLibre, and Pearson Jumped Today Motley Fool
01:57PM  Why Immunomedics, Inc. Rocketed Today Motley Fool
10:42AM  Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated TheStreet.com
08:46AM  Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value Business Wire
Apr-25-17 04:18PM  Immunomedics, Inc. Value Analysis (NASDAQ:IMMU) : April 25, 2017 Capital Cube +6.98%
Apr-24-17 08:41AM  Immunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : April 24, 2017 Capital Cube
Apr-21-17 06:52PM  Why Immunomedics, Inc. Got Hammered Today Motley Fool -13.04%
Apr-05-17 07:00AM  Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients With Metastatic Small-Cell Lung Cancer Who Are Sensitive or Resistant to First-Line Chemotherapy GlobeNewswire
07:00AM  Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients With Metastatic Small-Cell Lung Cancer Who Are Sensitive or Resistant to First-Line Chemotherapy
Apr-04-17 01:00PM  Immunomedics Presents Preclinical Study That Demonstrates Increased SN-38 Delivery With Labetuzumab Govitecan (IMMU-130) Compared With Irinotecan GlobeNewswire
01:00PM  Immunomedics Presents Preclinical Study That Demonstrates Increased SN-38 Delivery With Labetuzumab Govitecan (IMMU-130) Compared With Irinotecan
09:24AM  Biotech Movers: Paratek Spikes 34% TheStreet.com
09:24AM  Biotech Movers: Paratek Spikes 34%
08:00AM  Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome Chemoresistant Tumors With Moderate to Strong Trop-2 Expression GlobeNewswire
08:00AM  Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome Chemoresistant Tumors With Moderate to Strong Trop-2 Expression
Mar-28-17 02:06PM  Battle in the Boardroom: What's Next for Immunomedics Motley Fool
02:06PM  Battle in the Boardroom: What's Next for Immunomedics at Motley Fool
09:30AM  Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and Immunomedics Accesswire
08:26AM  Why Shares of Immunomedics Inc Are up an Astounding 89% in 2017 Motley Fool
08:26AM  Why Shares of Immunomedics Inc Are up an Astounding 89% in 2017 at Motley Fool
Mar-21-17 03:02PM  Billionaires' Best Healthcare Stock Picks of 2017 (So Far) Motley Fool
03:02PM  Billionaires' Best Healthcare Stock Picks of 2017 (So Far) at Motley Fool
Mar-17-17 02:46PM  3 Companies That Need to Kick Their CEO to the Curb Motley Fool
02:46PM  3 Companies That Need to Kick Their CEO to the Curb at Motley Fool
Mar-16-17 01:13PM  IMMUNOMEDICS INC Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders
Mar-15-17 09:32AM  Biotech Premarket Movers: Arena, Immunomedics, Aralez
08:00AM  Immunomedics Announces Publication of Results in Journal of Clinical Oncology, Demonstrating Treatment With Sacituzumab Govitecan (IMMU-132) Produces Early and Durable Responses in Patients With Metastatic Triple-Negative Breast Cancer PR Newswire
Mar-10-17 02:27PM  Heres Whats Moving Immunomedics, Inc. (IMMU) And Ocera Therapeutics Inc (OCRX) at Insider Monkey +5.49%
02:25PM  Judge Blocks $2B Immunomedics-Seattle Genetics Deal (IMMU,SGEN) at Investopedia
09:30AM  Markets Rally Late to Close in the Green: Today's Research Reports on Immunomedics and VIVUS Accesswire
Mar-09-17 04:39PM  Why Immunomedics, Inc. Jumped Higher Today at Motley Fool +19.48%
04:37PM  Why Marathon Oil, Signet Jewelers, and Immunomedics Jumped Today at Motley Fool
04:35PM  IMMUNOMEDICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
04:24PM  Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted
02:35PM  Judge puts Seattle Genetics' $2 billion deal with Immunomedics on hold at bizjournals.com
01:33PM  Immunomedics Soars on Injunction Against Seattle Genetics Deal
Mar-06-17 08:47AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
07:48AM  Seattle Genetics to resume trials as FDA lifts clinical hold Reuters
Mar-03-17 12:21PM  Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote
12:00PM  Stockholders Endorse venBios Case for Meaningful Change at Immunomedics Business Wire
11:50AM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:19AM  Immunomedics Board Institutes Measures As Stockholder Fiduciaries To Preserve Their Best Business Judgment To Protect The Rights Of All Stockholders PR Newswire
Mar-02-17 01:51PM  venBio Encourages Stockholders to Vote for Change Business Wire
12:06PM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:23AM  Immunomedics Outlines Revised Settlement Offer Rejected By venBio; Announces Actions That Are In The Best Interests Of All Stockholders PR Newswire
Feb-28-17 08:00AM  Immunomedics to Present at Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-27-17 08:24AM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  Immunomedics Issues Open Letter Highlighting the Clear Decision to Vote for Immunomedics to Ensure Continued Value Creation GlobeNewswire
Feb-23-17 05:34PM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
11:53AM  Immunomedics Sues Board Over Seattle Genetics Deal at Investopedia
11:30AM  Immunomedics Announces Companys Immune Checkpoint Inhibitor Enhances Anti-Tumor Potency of T-Cell-Redirecting Bispecific Antibodies GlobeNewswire
Feb-22-17 08:32AM  venBio Sends Letter to Immunomedics Stockholders Business Wire
Feb-21-17 08:45AM  IMMUNOMEDICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -5.24%
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDENBERG DAVID MSee RemarksSep 01Sale12.9010,000129,0003,395,578Sep 05 07:10 PM
GOLDENBERG CYNTHIA LDirectorSep 01Sale12.9010,000129,000778,219Sep 05 07:10 PM
GOLDENBERG CYNTHIA LDirectorAug 31Sale12.3810,000123,750788,219Sep 05 07:10 PM
GOLDENBERG DAVID MSee RemarksAug 31Sale12.3810,000123,7503,405,578Sep 05 07:10 PM
GOLDENBERG DAVID MSee RemarksAug 28Sale11.5610,000115,5913,415,578Aug 28 08:54 PM
GOLDENBERG CYNTHIA LDirectorAug 28Sale11.5215,000172,841798,219Aug 28 08:54 PM
GOLDENBERG CYNTHIA LDirectorAug 24Sale10.2425,000256,105813,219Aug 28 08:54 PM
GOLDENBERG DAVID MSee RemarksAug 23Sale9.5010,00095,0003,455,578Aug 23 09:00 PM
GOLDENBERG CYNTHIA LDirectorAug 23Sale9.5010,00095,000838,219Aug 23 09:00 PM
GOLDENBERG CYNTHIA LDirectorAug 22Sale9.5010,00095,000848,219Aug 23 09:00 PM
GOLDENBERG DAVID MSee RemarksAug 22Sale9.5010,00095,0003,465,578Aug 23 09:00 PM
GOLDENBERG DAVID MSee RemarksAug 21Sale8.9720,000179,4263,475,578Aug 23 09:00 PM
GOLDENBERG CYNTHIA LDirectorAug 21Sale8.9720,000179,426858,219Aug 23 09:00 PM